AGÕæÈ˹ٷ½

STOCK TITAN
  1. Home
  2. Sec-filings
  3. ITRM
  4. [PRE 14A] Iterum Therapeutics plc Ordinary Share Preliminary Proxy Statement

[PRE 14A] Iterum Therapeutics plc Ordinary Share Preliminary Proxy Statement

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
PRE 14A

Filing content is currently unavailable.

Source:

Stock ITRM logo
Iterum Therapeutics Plc

NASDAQ:ITRM

ITRM Rankings

#5398 Ranked by Market Cap
N/A Ranked by Dividends

ITRM Latest News

Aug 20, 2025
Iterum Therapeutics launches ORLYNVAH�, the first and only oral penem antibiotic in the U.S.
Aug 5, 2025
Iterum Therapeutics Reports Second Quarter 2025 Financial Results
Jul 29, 2025
Iterum Therapeutics to Report Second Quarter 2025 Financial Results on August 5, 2025
Jul 2, 2025
Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Jun 30, 2025
Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH� Launch and Commercial Growth

ITRM Latest SEC Filings

Aug 20, 2025
[8-K] Iterum Therapeutics plc Ordinary Share Reports Material Event
Aug 12, 2025
[Form 4] Iterum Therapeutics plc Ordinary Share Insider Trading Activity
Aug 5, 2025
[10-Q] Iterum Therapeutics plc Ordinary Share Quarterly Earnings Report
Aug 5, 2025
[8-K] Iterum Therapeutics plc Ordinary Share Reports Material Event
Aug 4, 2025
[8-K] Iterum Therapeutics plc Ordinary Share Reports Material Event

ITRM Stock Data

38.85M
44.25M
0.96%
8.58%
4.9%
Biotechnology
Pharmaceutical Preparations
Ireland
DUBLIN 1